Xilio Therapeutics appoints Cheryl Blanchard to Board; Rossi resigns

Xilio Therapeutics, Inc.

Cheryl Blanchard elected as Class III director effective April 15, 2026; term expires at 2027 annual meeting.
Blanchard appointed chair of Compensation Committee and member of Audit Committee.
Blanchard receives $40k annual cash retainer, $12k for Comp chair, $7.5k for Audit; initial option for 10k shares vesting over 3 years.
Christina Rossi resigned from Board on April 15, 2026; resignation not due to any disagreement with company.
Board adopted amended Non-Employee Director Compensation Policy effective April 15, 2026 (Exhibit 10.1).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.